Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes

Nephron - Physiology

Volumn 103, Issue 4, 2006, Pages

  Hanada, Kazuhiko ^a   Ogawa, Rie ^a   Son, Kishin ^a   Sasaki, Yuuki ^a   Kikkawa, Akashi ^a   Ichihara, Shiho ^a   Ogata, Hiroyasu ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

3 Indoleacetic acid; 3 Indoxylsulfate; Hepatocytes; Metabolism; Microsomes; Nicardipine; Pharmacokinetics; Testosterone to 6 hydroxyltestosterone; Uremic substances

Indexed keywords

3 INDOXYLSULFATE; 6BETA HYDROXYTESTOSTERONE; ETHOXYRESORUFIN; INDICAN; INDOLEACETIC ACID; NICARDIPINE; RESORUFIN; SULFATE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG METABOLISM; GLUCURONIDATION; HEMODIALYSIS; HUMAN; HUMAN CELL; LIVER CELL; LIVER METABOLISM; LIVER MICROSOME; METABOLIC RATE; OXIDATION; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONOSYLTRANSFERASE; HEPATOCYTES; HUMANS; INDICAN; INDOLEACETIC ACIDS; MICROSOMES, LIVER; NICARDIPINE;

EID: 33746364150     PISSN: 16602137     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092919     Document Type: Article

References (33)

1. Tilstone WJ, Fine A: Furosemide kinetics in renal failure. Clin Pharmacol Ther 1978;23:644-650.
2. Keefe DL, Yee YG, Kates RE: Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther 1981;29:21-26.
3. Vanholder R, Landschoot NV, De Smet R, Schools A, Ringoir S: Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 1988;33:996-1004.
4. Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, Miyazaki M: Plasma protein binding of tamsulosin hydrochloride in renal disease: role of alphal-acid glycoprotein and possibility of binding interactions. Eur J Clin Pharmacol 1999;55:437-443.
5. Sakai T, Takadate A, Otagiri M: Characterization of binding site of uremic toxins on human serum albumin. Biol Pharm Bull 1995;18:1755-1761.
6. Rowland M, Tozer N: Clinical Pharmacokinetics: Concepts and Applications, ed 3. PA, USA, Williams & Wilkins, 1995.
7. Mooy J, Schols M, Baak MV, Hooff MV, Muytjens A, Rahn KH: Pharmacokinetics of verapamil in patients with renal failure. Eur J Clin Pharmacol 1985;28:405-410.
8. Kleinbloesem CH, Brummelen PV, Harten JV, Danhof M, Breimer DD: Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. Clin Pharmacol Ther 1985;37:563-574.
9. Ahmed JH, Grant AC, Rodger RSC, Murray GR, Elliott HL: Inhibitory effect of uremia on the hepatic clearance and metabolism of nicardipine. Br J Clin Pharmacol 1991;32:57-62.
10. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL: Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 2003;73:427-434.
11. Leblond FA, Giroux L, Villeneuve JP, Pichette V: Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Disposit 2000;28:1317-1320.
12. Leblond FA, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V: Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001;12:326-332.
13. Guevin C, Michaud J, Naud J, Leblond FA, Pichette V: Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 2002;137: 1039-1046.
14. Michaud J, Dube P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V: Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 2005;144:1067-1077.
15. Leclercq I, Desager JP, Vandenplas C, Horsmans Y: Fast determination of low-level cytochrome P-450 1A1 activity by high-performance liquid chromatography with fluorescence or visible absorbance detection. J Chromatogr B 1996;681:227-232.
16. Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y: Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos 2000;28:475-481.
17. Zomorodi K, Houston JB: Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. Br J Clin Pharmacol 1996;42:157-162.
18. Schmider J, Greenblatt DJ, Fogelman SM, Moltke LLV, Shader RI: Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 1997;18:227-240.
19. Draper AJ, Madan A, Smith K, Parkinson A: Development of a non-high pressure liquid chromatography assay to determine testosterone hydroxylase (CYP3A) activity in human liver microsomes. Drug Metab Dispos 1998;26:299-304.
20. Miners JO, Lillywhite KL, Matthews AP, Jones ME, Birkett DJ: Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. Biochem Pharmacol 1988;37:665-671.
21. Hanioka N, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M: Determination of UDP-glucuronosyltransferase UGT1A6 activity in human and rat liver microsomes by HPLC with UV detection. J Pharm Biomed Anal 2001;25:65-75.
22. Coffman BL, Rios GR, King CD, Tephly TR: Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997;25:1-4.
23. Azzam RM, Notarianni LJ, Ali HM: Rapid and simple chromatographic method for the determination of diazepam and its major metabolites in human plasma and urine. J Chromatogr B 1998;708:304-309.
24. Nagai N, Kawakubo T, Kaneko F, Ishii M, Shinohara R, Saito Y, Shimamura H, Ohnishi A, Ogata H: Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population. Biopharm Drug Dispos 1996;17:421-433.
25. Chittur SV, Tracy TS: Rapid and sensitive high-performance liquid chromatographic assay for 6-hydroxychlorzoxazone and chlorzoxazone in liver microsomes. J Chromatogr B 1997;693:479-483.
26. Sanwald P, Blankson EA, Dulery BD, Schoun J, Huebert ND, Dow J: Isocratic high-performance liquid chromatographic method for the separation of testosterone metabolites. J Chromatogr B 1995;672:207-215.
27. Venkatakrishnan K, Moltke LL, Greenblatt DJ: Human drug metabolism and the cytochrome P450: application and relevance of in vitro models. J Clin Pharmacol 2001;41:1149-1179.
28. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 2000;55:843-852.
29. Uchida N, Kurata N, Shimada K, Nishimura Y, Yasuda K, Hashimoto M, Uchida E, Yasuhara H: Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy. Jpn J Pharmacol 1995;68:431-439.
30. Lim CF, Bernard BF, Jong MD, Docter R, Krenning EP, Hennemann G: A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 1993;76:318-324.
31. Lesaffer G, Smet RD, Lameire N, Dhondt A, Duym P, Vanholder R: Intradislytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000;15:50-57.
32. Kato A, Odamaki M, Hishida A: Association between blood indoxyl sulfate and carbonyl stress marker in hemodialysis patients. Clin Nephrol 2003;60:161-167.
33. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C and Zidek W, European Uremic Toxin Work Group (EUTox): Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.